



that we have reported earlier only the sulphonamide inhibition profile of this enzyme<sup>16</sup>.

## 2. Materials and methods

### 2.1. Construction of $\beta$ -CA fusion protein

*Anopheles gambiae* cDNA was obtained from Professor Michael Lehane (Liverpool School of Tropical Medicine, UK). The  $\beta$ -CA gene was retrieved from NCBI protein databases using Blast<sup>17</sup>, <http://blast.ncbi.nlm.nih.gov/Blast.cgi>. The full-length  $\beta$ -CA gene was identified and amplified from cDNA by PCR using Phusion<sup>TM</sup> Hot Start High Fidelity DNA Polymerase (Finnzymes, Espoo, Finland). The detailed PCR method has been described previously by our group<sup>16</sup>. The PCR product band was separated from the gel and dissolved using Illustra<sup>TM</sup> GFX PCR DNA and GEL Band Purification Kit (GE Healthcare Life Sciences, Buckinghamshire, UK). Validity of the PCR product was verified by sequencing.

For recombinant protein production, the  $\beta$ -CA gene was constructed and cloned into the pFastBac1<sup>TM</sup> vector. The forward primer used in the initial amplification of the  $\beta$ -CA gene was 5'-CGCGGATCCATGGAGCGTATATTGCGAGGC-3' (F2), and the reverse primer was 5'-GCCCTCGAGTTAATGGTGGTGATGGTGGGAACC-ACGGGGCACCAAGCAATAGTATCGCCGTACCTC-3' (R2). The latter primer contains nucleotide repeats to create the C-terminal poly-histidine tag with six histidines. In addition, the forward primer contained the restriction site for BamHI and the reverse primer for XhoI. The reverse primer also contained the nucleotide sequence encoding thrombin cleavage site. The PCR program was as follows: 98 °C for 30 s; then 35 cycles of 98 °C for 10 s, 62 °C for 15 s, and 62 °C for 30 s, and finally 72 °C for 5 min.

The PCR product was run on an agarose gel, and the obtained band was purified. pFastBac<sup>TM</sup>1 plasmid (Invitrogen, Carlsbad, CA) and the PCR product were digested at +37 °C overnight with BamHI and XhoI restriction enzymes (New England Biolabs, Ipswich, MA). The digested plasmid and PCR product containing full-length recombinant *A. gambiae*  $\beta$ -CA gene were purified and then ligated overnight at +4 °C using T4 DNA ligase (New England Biolabs). The ligated product was transformed into TOP10 bacteria (Invitrogen, Helsinki, Finland). Overnight cultures (8 ml) were made from these colonies, and plasmids were purified using a QIAprep Spin Miniprep Kit<sup>TM</sup> (Qiagen, Hilden, Germany). The construction of baculoviral genomes encoding the recombinant proteins has been described previously<sup>18</sup>.

### 2.2. Production of *A. gambiae* $\beta$ -CA

The Sf9 insect cells were grown in Insect-Xpress protein-free cell culture medium (Lonza, Verviers, Belgium) in an orbital shaker at 27 °C (125 rpm) for 3 d after infection. Protein purification was performed after centrifugation (5000 × *g*, 20 °C, 8 min) from the supernatant. Purification was performed using the Protino<sup>®</sup> Ni-NTA Agarose (from Macherey-Nagel, Munich, Germany) under native binding conditions with wash and elution buffers made according to the manufacturer's instructions. The purification procedure per 400 ml of insect cell medium was as follows: 3 L of native binding buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 500 mM NaCl, pH 8.0) and 8 ml of the nickel-chelating agarose were added to the medium, and the His-tagged protein was then allowed to bind to the resin on a magnetic stirrer at 25 °C for 3 h. The resin was washed with 40 + 20 ml of washing buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 500 mM NaCl, 20 mM imidazole pH 8.0). The protein was then eluted with elution buffer (50 mM NaH<sub>2</sub>PO<sub>4</sub>, 500 mM NaCl, 250 mM imidazole, pH 8.0). After

this, the protein was transferred to 50 mM Tris-HCl, pH 7.5. To remove the His tag, the recombinant protein was treated with 150  $\mu$ L of resin-coupled thrombin (Thrombin CleanCleave KIT<sup>TM</sup>, Sigma, Milan, Italy) per 1 mg of protein with gentle shaking at +20 °C overnight, according to the manufacturer's instructions. Protein concentration was determined using the DC Protein Assay<sup>TM</sup> (Bio-Rad, Berlin, Germany) with three different dilutions.

### 2.3. CA activity measurements and inhibition studies

An Applied Photophysics stopped-flow instrument has been used for assaying the CA catalysed CO<sub>2</sub> hydration activity<sup>19</sup>. Phenol red (at a concentration of 0.2 mM) has been used as indicator, working at the absorbance maximum of 557 nm, with 20 mM Hepes (pH 7.6) or 20 mM TRIS (pH 8.3) as buffers, and 20 mM NaClO<sub>4</sub> (for maintaining constant the ionic strength). Perchlorate is not inhibiting the enzyme at concentrations up to 100 mM, data not shown, as for many other CAs investigated earlier by our group<sup>20</sup>, following the initial rates of the CA-catalysed CO<sub>2</sub> hydration reaction for a period of 10–100 s<sup>19</sup>. The CO<sub>2</sub> concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and inhibition constants. For each inhibitor at least six traces of the initial 5–10% of the reaction have been used for determining the initial velocity. The uncatalysed rates were determined in the same manner and subtracted from the total observed rates. Stock solutions of inhibitors (10 mM) were prepared in distilled-deionised water and dilutions up to 0.01 nM were done thereafter with the assay buffer. Inhibitor and enzyme solutions were preincubated together for 15 min at room temperature prior to assay, in order to allow for the formation of the E-I complex. The inhibition constants were obtained by non-linear least-squares methods using PRISM 3 and the Cheng–Prusoff equation, as reported earlier<sup>21–23</sup>, and represent the mean from at least three different determinations. All CA isoforms were recombinant ones obtained in house as reported earlier<sup>9,16</sup>. The concentration of AgaCA used in the experiments reported in the paper was of 13.2 nM.

## 3. Results and discussion

As shown in the introduction, there exists only few studies on insect CAs. Apart our initial reports<sup>9,16</sup> on the presence of a  $\beta$ -CA in *Drosophila melanogaster* and *Anopheles gambiae*, some sulphonamide and dithiocarbamate studies were reported for the inhibition of the first enzyme<sup>24</sup>, but no other inhibition studies (except the sulphonamide ones)<sup>16</sup> are available for AgaCA. It should be mentioned that recently a CA was also reported and its activity/inhibition investigated from another insect species, the honey bee *Apis mellifera*<sup>25</sup>. In this paper, we report the first extensive anion inhibition study of the  $\beta$ -CA from *Anopheles gambiae*, AgaCA, with a large series of simple and complex anions.

In the previous work<sup>16</sup>, we observed that AgaCA has a significant catalytic activity for the physiologic, CO<sub>2</sub> hydration reaction to bicarbonate and protons, with the kinetic parameters shown in Table 1. AgaCA has a catalytic activity which is similar to that of the human cytosolic isoform hCA I, and is also inhibited quite effectively by the sulphonamide. The widely clinically used compound, acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulphonamide), showed an inhibition constant of 27.3 nM (Table 1).

Inorganic anions constitute an important class of CA inhibitors (CAIs)<sup>20</sup>. Both inorganic, complexing anions and more complex anions were investigated for their interaction with a large number of enzymes belonging to all CA families<sup>20</sup>. Such studies may lead

**Table 1.** Kinetic parameters for the CO<sub>2</sub> hydration reaction catalysed by the human cytosolic isozymes hCA I and II ( $\alpha$ -class CAs) and the  $\beta$ -CAs from *Drosophila melanogaster* (DmBCA) and *Anopheles gambiae* (AgaCA) measured at 20 °C, pH 7.6 in 20 mM HEPES buffer (for hCA I and II) and 20 °C, pH 8.3 in 20 mM TRIS buffer (for the  $\beta$ -CAs), in the presence 20 mM NaClO<sub>4</sub> (for maintaining constant ionic strength). Inhibition data with the clinically used sulphonamide acetazolamide (5-acetamido-1,3,4-thiadiazole-2-sulphonamide) are also provided.

Enzyme	Activity level	Class	$k_{cat}$ (s <sup>-1</sup> )	$k_{cat}/K_m$ (M <sup>-1</sup> × s <sup>-1</sup> )	$K_i$ (acetazolamide) (nM)
hCA I <sup>a</sup>	Moderate	$\alpha$	$2.0 \times 10^5$	$5.0 \times 10^7$	250
hCA II <sup>a</sup>	Very high	$\alpha$	$1.4 \times 10^6$	$1.5 \times 10^8$	12
DmBCA <sup>b</sup>	High	$\beta$	$9.5 \times 10^5$	$1.1 \times 10^8$	516
AgaCA <sup>c</sup>	Moderate	$\beta$	$7.2 \times 10^5$	$5.6 \times 10^7$	27.3

<sup>a</sup>From ref.<sup>20a</sup>.

<sup>b</sup>From ref.<sup>9</sup>.

<sup>c</sup>From ref.<sup>16</sup>.

**Table 2.** Inhibition constants of anionic inhibitors against isozymes hCA I, II ( $\alpha$ -CA class), and DmBCA (*D. melanogaster*) and AgaCA (*A. gambiae*) for the CO<sub>2</sub> hydration reaction, at 20 °C<sup>19</sup>.

Inhibitor	$K_i$ [mM] <sup>e</sup>			
	hCA I <sup>a</sup>	hCA II <sup>a</sup>	DmBCA <sup>b</sup>	AgaCA <sup>c</sup>
F <sup>-</sup>	>300	>300	0.80	9.42
Cl <sup>-</sup>	6	200	0.97	8.74
Br <sup>-</sup>	4	63	1.04	>200
I <sup>-</sup>	0.3	26	1.18	>200
CNO <sup>-</sup>	0.0007	0.03	0.73	9.46
SCN <sup>-</sup>	0.2	1.6	1.28	6.41
CN <sup>-</sup>	0.0005	0.02	0.67	8.34
N <sub>3</sub> <sup>-</sup>	0.0012	1.5	1.12	12.40
HCO <sub>3</sub> <sup>-</sup>	12	85	26.90	4.34
CO <sub>3</sub> <sup>2-</sup>	15	73	0.86	9.25
NO <sub>3</sub> <sup>-</sup>	7	35	43.74	6.50
NO <sub>2</sub> <sup>-</sup>	8.4	63	28.60	4.55
HS <sup>-</sup>	0.0006	0.04	1.01	25.10
HSO <sub>3</sub> <sup>-</sup>	18	89	1.29	>200
SO <sub>4</sub> <sup>2-</sup>	63	>200	1.36	9.03
ClO <sub>4</sub> <sup>-</sup>	>200	>200	>200	>200
SnO <sub>3</sub> <sup>2-</sup>	0.57	0.83	nt	1.80
SeO <sub>4</sub> <sup>2-</sup>	118	112	nt	9.41
TeO <sub>4</sub> <sup>2-</sup>	0.66	0.92	nt	4.96
P <sub>2</sub> O <sub>7</sub> <sup>4-</sup>	25.8	48.5	nt	8.52
V <sub>2</sub> O <sub>7</sub> <sup>4-</sup>	0.54	0.57	nt	7.98
B <sub>4</sub> O <sub>7</sub> <sup>2-</sup>	0.64	0.95	nt	7.95
ReO <sub>4</sub> <sup>-</sup>	0.11	0.75	nt	>200
RuO <sub>4</sub> <sup>-</sup>	0.10	0.69	nt	>200
S <sub>2</sub> O <sub>8</sub> <sup>2-</sup>	0.11	0.084	nt	>200
SeCN <sup>-</sup>	0.0085	0.086	nt	8.68
CS <sub>3</sub> <sup>2-</sup>	0.0087	0.0088	nt	8.19
Et <sub>2</sub> NCS <sub>2</sub> <sup>-</sup>	0.79	3.1	nt	0.65
H <sub>2</sub> NSO <sub>2</sub> NH <sub>2</sub>	0.31	1.13	0.15	0.054
H <sub>2</sub> NSO <sub>3</sub> H <sup>d</sup>	0.021	0.39	2.45	0.021
Ph-B(OH) <sub>2</sub>	58.6	23.1	22.39	0.047
Ph-AsO <sub>3</sub> H <sub>2</sub> <sup>d</sup>	31.7	49.2	32.60	0.084

<sup>a</sup>From ref.<sup>20a</sup>.

<sup>b</sup>From ref.<sup>9</sup>.

<sup>c</sup>This work.

<sup>d</sup>As sodium salt; nt: not tested.

<sup>e</sup>Errors in the range of 5–10% of the shown data, from three different assays, by a CO<sub>2</sub> hydration stopped-flow assay<sup>19</sup>.

to the discovery of novel classes of pharmacologically relevant CAIs: indeed, the dithiocarbamates were discovered, considering the simple anion trithiocarbonate (CS<sub>3</sub><sup>2-</sup>) as an inhibitor, and showed significant *in vitro* and *in vivo* activities in pathologies related to CA dysregulation, such as glaucoma<sup>26</sup>.

In Table 2, the inhibition of AgaCA with a panel of such anions is shown. Inhibition data for the widespread cytosolic isoforms hCA I and II, as well as for the enzyme from *D. melanogaster*, are

also shown, for comparison reasons. The following may be noted from the inhibition data of Table 2:

(i) Anions with low propensity for inhibiting AgaCA were bromide, iodide, bisulphite, perchlorate, perrhenate, perruthenate, and peroxydisulphate, which showed  $K_i$ s > 200 mM. Whereas perchlorate is generally the anion with less affinity for metal ions in solution and metalloenzyme (in fact it does not inhibit significantly any CA investigated so far)<sup>20</sup>, the data for the heavy halogenides and bisulphite are rather surprising, considering the fact that iodide and bromide are rather effective hCA I and DmBCA inhibitors (Table 2). Bisulphite is a weak hCA I and II inhibitor but it is more effective as a DmBCA inhibitor.

(ii) Azide and hydrogensulphide, anions which show a high affinity for many metal ions<sup>20</sup>, were rather weak AgaCA inhibitors, with  $K_i$ s of 12.4–25.1 mM. They were much more effective as DmBCA inhibitors and are micromolar hCA I inhibitors (Table 2). Thus, there are significant differences in the affinity of these inhibitors for various CAs, with the mosquito enzyme definitely less sensitive to these inhibitors compared to other insect or human CAs.

(iii) Most of the investigated anions showed inhibition constants in the range of 1.80–9.46 mM, being thus weak CAIs, but normally this is the range in which most simple/complex anions interact with most CAs<sup>20</sup>. They include fluoride, chloride, cyanate, thiocyanate, cyanide, bicarbonate, carbonate, nitrite, nitrate, sulphate, stannate, selenate, tellurate, diphosphate, divanadate, tetraborate, selenocyanide, and trithiocarbonate (Table 2). It should be observed that this series includes both anions with a high affinity for complexing metal ions (such as cyanate, thiocyanate, and cyanide) as well as anions with lower affinity for cations, such as nitrite, nitrate, and sulphate. It is interesting to note that for the halogenides, those incorporating light elements (F, Cl) were more effective than the halogenides incorporating heavy elements, which is opposite to the inhibitory effects observed with these anions against hCA I and II (Table 2). Bicarbonate was two times better as a AgaCA inhibitor compared with carbonate, whereas sulphate, which is a weak hCA I and II inhibitor, showed a <10 mM activity against AgaCA.

(iii) *N,N*-Diethyldithiocarbamate was a submillimolar AgaCA inhibitor, with a  $K_i$  of 0.65 mM, being thus much more effective than trithiocarbonate ( $K_i$  of 8.19 mM) from which it is derived.

(iv) The most effective AgaCA inhibitors were sulphamide, sulphamic acid, phenylboronic acid, and phenylarsonic acid, with inhibition constants in the range of 21–84  $\mu$ M. These compounds are known to act as efficient CAIs against many CAs and were used as leads to obtain potent inhibitors, some of which inhibit these enzymes in the low nanomolar range<sup>27</sup>. Indeed, these simple molecules incorporate zinc-binding functions of the sulphonamide, sulphamide, sulphamate, boronic acid, etc., which have been extensively employed to design highly effective CAIs<sup>27</sup>.

## 4. Conclusions

We report here an anion inhibition study of the  $\beta$ -class CA, AgaCA, from the mosquito *Anopheles gambiae*, the vector responsible of malaria transmission. A series of simple as well as complex inorganic anions, together with small molecules known to interact with CAs were included in the study. Bromide, iodide, bisulphite, perchlorate, perrhenate, perruthenate, and peroxydisulphate were ineffective AgaCA inhibitors, with  $K_i$ s > 200 mM. Fluoride, chloride, cyanate, thiocyanate, cyanide, bicarbonate, carbonate, nitrite, nitrate, sulphate, stannate, selenate, tellurate, diphosphate, divanadate, tetraborate, selenocyanide, and trithiocarbonate showed  $K_i$ s

in the range of 1.80–9.46 mM, whereas *N,N*-diethyldithiocarbamate was a submillimolar AgaCA inhibitor, with a  $K_i$  of 0.65 mM. The most effective AgaCA inhibitors were sulphamide, sulphamic acid, phenylboronic acid, and phenylarsonic acid, with inhibition constants in the range of 21–84  $\mu$ M. The control of insect vectors responsible of the transmission of many protozoan diseases is rather difficult nowadays, and finding agents which can interfere with these processes, as the enzyme inhibitors investigated here, may arrest the spread of these diseases worldwide.

## Acknowledgements

Authors want to thank Professor Michael Lehane (Liverpool School of Tropical Medicine, UK) for providing *A. gambiae* cDNA. Authors also want to thank Aulikki Lehmus for skillful technical assistance.

## Disclosure statement

The authors do not declare any conflict of interest.

## Funding

The work in our laboratories is supported by the competitive Research Funding of the Tampere University Hospital and the grants from the Academy of Finland, and Sigrid Juselius Foundation.

## References

- Whitty CJ, Chiodini PL, Laloo DG. Investigation and treatment of imported malaria in non-endemic countries. *BMJ* 2013;346:f2900.
- a) Sly WS, Hu PY. Human carbonic anhydrases and carbonic anhydrase deficiencies. *Annu Rev Biochem* 1995;64:375–401. b) Supuran CT. Carbonic anhydrases: from biomedical applications of the inhibitors and activators to biotechnological use for CO<sub>2</sub> capture. *J Enzyme Inhib Med Chem* 2013;28:229–30. c) Supuran CT. How many carbonic anhydrase inhibition mechanisms exist? *J Enzyme Inhib Med Chem* 2016;31:345–60. d) Alterio V, Di Fiore A, D'Ambrosio K, et al. Multiple binding modes of inhibitors to carbonic anhydrases: how to design specific drugs targeting 15 different isoforms? *Chem Rev* 2012;112:4421–68.
- a) Xu Y, Feng L, Jeffrey PD, et al. Structure and metal exchange in the cadmium carbonic anhydrase of marine diatoms. *Nature* 2008;452:56–61. b) Alterio V, Langella E, Viparelli F, et al. Structural and inhibition insights into carbonic anhydrase CDCA1 from the marine diatom *Thalassiosira weissflogii*. *Biochimie* 2012;94:1232–41.
- a) Lane TW, Saito MA, George GN, et al. Biochemistry: a cadmium enzyme from a marine diatom. *Nature* 2005;435:42. b) Del Prete S, Vullo D, De Luca V, et al. Biochemical characterization of the  $\delta$ -carbonic anhydrase from the marine diatom *Thalassiosira weissflogii*, TweCA. *J Enzyme Inhib Med Chem* 2014;29:906–11.
- a) Macauley SR, Zimmerman SA, Apolinario EE, et al. The archetype gamma-class carbonic anhydrase (Cam) contains iron when synthesized in vivo. *Biochemistry* 2009;48:817–9. b) Zimmerman SA, Ferry JG, Supuran CT. Inhibition of the archaeal beta-class (Cab) and gamma-class (Cam) carbonic anhydrases. *Curr Top Med Chem* 2007;7:901–8.
- a) Tripp BC, Bell CB, Cruz F, et al. A role for iron in an ancient carbonic anhydrase. *J Biol Chem* 2004;279:6683–7. b) Innocenti A, Zimmerman S, Ferry JG, et al. Carbonic anhydrase inhibitors. Inhibition of the zinc and cobalt gamma-class enzyme from the archaeon *Methanosarcina thermophila* with anions. *Bioorg Med Chem Lett* 2004;14:3327–31.
- a) Capasso C, Supuran CT. An overview of the alpha-, beta- and gamma-carbonic anhydrases from Bacteria: can bacterial carbonic anhydrases shed new light on evolution of bacteria? *J Enzyme Inhib Med Chem* 2015;30:325–32. b) Supuran CT, Capasso C. Carbonic anhydrase from *Porphyromonas Gingivalis* as a drug target. *Pathogens* 2017;6:E30. c) Capasso C, Supuran CT. Inhibition of bacterial carbonic anhydrases as a novel approach to escape drug resistance. *Curr Top Med Chem* 2017;17:1237–48. d) Supuran CT, Capasso C. New light on bacterial carbonic anhydrases phylogeny based on the analysis of signal peptide sequences. *J Enzyme Inhib Med Chem* 2016;31:1254–60. e) Aspatwar A, Hammarén M, Koskinen S, et al.  $\beta$ -CA-specific inhibitor dithiocarbamate Fc14-584B: a novel antimycobacterial agent with potential to treat drug-resistant tuberculosis. *J Enzyme Inhib Med Chem* 2017;32:832–40.
- a) Supuran CT. Structure and function of carbonic anhydrases. *Biochem J* 2016;473:2023–32. b) Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. *Nat Rev Drug Discov* 2008;7:168–81. c) Vullo D, Kumar RSS, Scozzafava A, et al. Sulphonamide inhibition studies of the  $\beta$ -carbonic anhydrase from the bacterial pathogen *Clostridium perfringens*. *J Enzyme Inhib Med Chem* 2018;33:31–6. d) Supuran CT. *Legionella pneumophila* carbonic anhydrases: underexplored antibacterial drug targets. *Pathogens* 2016;5:E44.
- Syrjanen L, Tolvanen M, Hilvo M, et al. Characterization of the first beta-class carbonic anhydrase from an arthropod (*Drosophila melanogaster*) and phylogenetic analysis of beta-class carbonic anhydrases in invertebrates. *BMC Biochem* 2010;11:28.
- Fasseas MK, Tsikou D, Fletmetakis E, Katinakis P. Molecular and biochemical analysis of the beta class carbonic anhydrases in *Caenorhabditis elegans*. *Mol Biol Rep* 2010;37:2941–50.
- Syrjanen L, Vermelho AB, de Almeida Rodrigues I, et al. Cloning, characterization and inhibition studies of a beta carbonic anhydrase from *Leishmania donovani* chagasi, the protozoan parasite responsible of leishmaniasis. *J Med Chem* 2013;56:7372–81.
- Seron TJ, Hill J, Linser PJ. A GPI-linked carbonic anhydrase expressed in the larval mosquito midgut. *J Exp Biol* 2004;207:4559–72.
- Smith KE, Vanekeris LA, Linser PJ. Cloning and characterization of AgCA9, a novel alpha-carbonic anhydrase from *Anopheles gambiae* Giles sensu stricto (Diptera: Culicidae) larvae. *J Exp Biol* 2007;210:3919–30.
- a) Krungkrai J, Supuran CT. The alpha-carbonic anhydrase from the malaria parasite and its inhibition. *Curr Pharm Des* 2008;631–40. b) Del Prete S, Vullo D, Fisher GM, et al. Discovery of a new family of carbonic anhydrases in the malaria pathogen *Plasmodium falciparum* – the  $\eta$ -carbonic anhydrases. *Bioorg Med Chem Lett* 2014;24:4389–96. c) Zolfaghari Emameh R, Barker H, Hytönen VP, et al. Beta carbonic anhydrases: novel targets for pesticides and anti-parasitic agents in agriculture and livestock husbandry. *Parasit Vectors* 2014;7:403.

15. Pan P, Vermelho AB, Capaci Rodrigues G, et al. Cloning, characterization, and sulfonamide and thiol inhibition studies of an alpha-carbonic anhydrase from *Trypanosoma cruzi*, the causative agent of chagas disease. *J Med Chem* 2013;56:1761–71.
16. Syrjänen L, Kuuslahti M, Tolvanen M, et al. The  $\beta$ -carbonic anhydrase from the malaria mosquito *Anopheles gambiae* is highly inhibited by sulfonamides. *Bioorg Med Chem* 2015;23:2303–9.
17. Altschul SF, Gish W, Miller W, et al. Basic local alignment search tool. *J Mol Biol* 1990;215:403–10.
18. Hilvo M, Baranauskiene L, Salzano AM, et al. Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. *J Biol Chem* 2008;283:27799–809.
19. Khalifah RG. The carbon dioxide hydration activity of carbonic anhydrase. I. Stop-flow kinetic studies on the native human isoenzymes B and C. *J Biol Chem* 1971;246:2561–73.
20. a) De Simone G, Supuran CT. (In)organic anions as carbonic anhydrase inhibitors. *J Inorg Biochem* 2012;111:117–29. b) Del Prete S, Vullo D, Osman SM, et al. Anion inhibitors of the  $\beta$ -carbonic anhydrase from the pathogenic bacterium responsible of tularemia, *Francisella tularensis*. *Bioorg Med Chem* 2017;25:4800–4. c) Nocentini A, Vullo D, Del Prete S, et al. Inhibition of the  $\beta$ -carbonic anhydrase from the dandruff-producing fungus *Malassezia globosa* with monothiocarbamates. *J Enzyme Inhib Med Chem* 2017;32:1064–70.
21. a) Scozzafava A, Briganti F, Mincione G, et al. Carbonic anhydrase inhibitors: synthesis of water-soluble, aminoacyl/dipeptidyl sulfonamides possessing long-lasting intraocular pressure-lowering properties via the topical route. *J Med Chem* 1999;42:3690–700. b) Puccetti L, Fasolis G, Vullo D, et al. Carbonic anhydrase inhibitors. Inhibition of cytosolic/tumor-associated carbonic anhydrase isozymes I, II, IX, and XII with Schiff's bases incorporating chromone and aromatic sulfonamide moieties, and their zinc complexes. *Bioorg Med Chem Lett* 2005;15:3096–101.
22. a) Scozzafava A, Menabuoni L, Mincione F, Supuran CT. Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino – polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties. *J Med Chem* 2002;45:1466–76. b) Pacchiano F, Aggarwal M, Avvaru BS, et al. Selective hydrophobic pocket binding observed within the carbonic anhydrase II active site accommodate different 4-substituted-ureido-benzenesulfonamides and correlate to inhibitor potency. *Chem Commun (Camb)* 2010;46:8371–3. c) Supuran CT, Mincione F, Scozzafava A, et al. Carbonic anhydrase inhibitors—Part 52. Metal complexes of heterocyclic sulfonamides: a new class of strong topical intraocular pressure-lowering agents in rabbits. *Eur J Med Chem* 1998;33:247–54.
23. a) Scozzafava A, Menabuoni L, Mincione F, et al. Carbonic anhydrase inhibitors: perfluoroalkyl/aryl-substituted derivatives of aromatic/heterocyclic sulfonamides as topical intraocular pressure-lowering agents with prolonged duration of action. *J Med Chem* 2000;43:4542–51. b) Abbate F, Winum JY, Potter BV, et al. Carbonic anhydrase inhibitors: X-ray crystallographic structure of the adduct of human isozyme II with EMATE, a dual inhibitor of carbonic anhydrases and steroid sulfatase. *Bioorg Med Chem Lett* 2004;14:231–4.
24. a) Syrjänen L, Tolvanen ME, Hilvo M, et al. Characterization, bioinformatic analysis and dithiocarbamate inhibition studies of two new  $\alpha$ -carbonic anhydrases, CAH1 and CAH2, from the fruit fly *Drosophila melanogaster*. *Bioorg Med Chem* 2013;21:1516–21. b) Syrjänen L, Parkkila S, Scozzafava A, Supuran CT. Sulfonamide inhibition studies of the  $\beta$  carbonic anhydrase from *Drosophila melanogaster*. *Bioorg Med Chem Lett* 2014;24:2797–801. c) Zolfaghari Emameh R, Syrjänen L, Barker H, et al. *Drosophila melanogaster*: a model organism for controlling Dipteran vectors and pests. *J Enzyme Inhib Med Chem* 2015;30:505–13.
25. Soydan E, Güler A, Bıyık S, et al. Carbonic anhydrase from *Apis mellifera*: purification and inhibition by pesticides. *J Enzyme Inhib Med Chem* 2017;32:47–50.
26. a) Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates: a new class of carbonic anhydrase inhibitors. Crystallographic and kinetic investigations. *Chem Commun (Camb)* 2012;48:1868–70. b) Carta F, Aggarwal M, Maresca A, et al. Dithiocarbamates strongly inhibit carbonic anhydrases and show antiglaucoma action *in vivo*. *J Med Chem* 2012;55:1721–30. c) Maresca A, Carta F, Vullo D, Supuran CT. Dithiocarbamates strongly inhibit the  $\beta$ -class carbonic anhydrases from *Mycobacterium tuberculosis*. *J Enzyme Inhib Med Chem* 2013;28:407–11.
27. a) Supuran CT. Bortezomib inhibits bacterial and fungal  $\beta$ -carbonic anhydrases. *Bioorg Med Chem* 2016;24:4406–9. b) Alterio V, Cadoni R, Esposito D, et al. Benzoxaborole as a new chemotype for carbonic anhydrase inhibition. *Chem Commun (Camb)* 2016;52:11983–6. c) Nocentini A, Cadoni R, Del Prete S, et al. Benzoxaboroles as efficient inhibitors of the  $\beta$ -carbonic anhydrases from pathogenic fungi: activity and modeling study. *ACS Med Chem Lett* 2017;8:1194–8.